Research

University of Texas Health Science Center at San Antonio – $50,000

Targeting RRNA Modification and SNORNA Function, A Novel Concept to Treat Aggressive Medulloblastoma

Children’s National Medical Center – $300,000

Multilamellar H3K27M RNA aggregates targeting diffuse midline glioma, including diffuse intrinsic pontine glioma.

Children's Hospital Los Angeles – $100,000

Targeting FOXR2 in Diffuse Midline Gliomas

University Hospital of Navarra - $100,000 USD, €92,637 EUR

Targeting Diffuse Midline Glioma vulnerabilities as a therapeutic strategy.

The Institute of Cancer Research – $111,445 USD / £85,976 GBP

Unravelling transcriptional plasticity as a non-genetic mechanism of drug resistance in DMG.

Cincinnati Children’s Hospital Medical Center - $200,000

Combining FLASH and immunotherapy to target medulloblastoma relapse

Emory University / Cincinnati Children's Hospital – $93,250

SUMOylation as a novel therapeutic target in DIPG

University of Chicago Medical Center / Washington University St. Louis – $100,000

Characterizing and Targeting ABL1 and ABL2 in Medulloblastoma Leptomeningeal Dissemination.

Icahn School of Medicine at Mount Sinai – $100,000

Targeting macrophages to improve the survival of DIPG

Children’s Hospital Colorado – $100,000

Dual targeting processive transcription for Myc-driven circuitry in medulloblastoma.

Princess Máxima Center for Pediatric Oncology – $98,306

Assessing the potential of the HDAC inhibitor givinostat ± radiotherapy for the treatment of diffuse midline glioma.

Nemours Children’s Hospital - $50,000

Treatment of Diffuse Intrinsic Pontine Glioma with the Oncolytic Zika Virus.

Icahn School of Medicine at Mount Sinai - $100,000

Preclinical evaluation of TP-0184 in an autochthonous mouse model of DIPG/DMG

The University of Alabama at Birmingham – $100,000

Intranasal Delivery of Targeting Nanotherapeutics for DIPG

Funding of PBTCF 2023 - $25,000